title: MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
abstract: MicroRNAs (miRNAs) are a class of highly conserved small noncoding RNAs that play pivotal roles at the post-transcriptional level in the biological function of various cancers, including breast cancer. In our study, miR-346 mimic, inhibitor, negative control or si-SRCIN1 were transfected into MCF-7 and MCF-7/Doc cells, respectively. Quantitative real time PCR (qRT-PCR) was used to measure miR-346 and SRCIN1 mRNA expressions and western blot was used to detect the expression of SRCIN1 in protein level. CCK-8 and colony formation were employed to verify cell viability and proliferation. Flow cytometry showed the apoptosis. Transwell was performed to detect migration and invasion. The luciferase reporter assay data showed the target correlation of miR-346 and SRCIN1. Firstly, we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues and there was significant inversed correlation between miR-346 and SRCIN1. Overexpression of miR-346 promoted cell proliferation, colony formation, migration and invasion, and reduced apoptosis, sensitivity to Docetaxel (Doc). SRCIN1 was identified as a direct target of miR-346, whose silencing promoted cell proliferation and the IC50 of Doc. Moreover, SRCIN1 silencing reduced the effect of miR-346 down-expression. Taken together, miR-346 may function as an oncogenic miRNA and mediate chemosensitivity to docetaxel through targeting SRCIN1 in breast cancer, targeted modulation of miR-346 expression may became a potential strategy for the treatment.
authors.affiliation: Xuzhou Medical University, Xuzhou, Xuzhou 221004, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China. Electronic address: yfanmm@foxmail.com.
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
authors.affiliation: Xuzhou Medical University, Xuzhou, Xuzhou 221004, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
authors.forename: Long-Ji
authors.initials: LJ
authors.lastname: Luo
authors.affiliation: Xuzhou Medical University, Xuzhou, Xuzhou 221004, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China; The First Clinical School of Nanjing Medical University, Nanjing 210009, China.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China; The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China.
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Yang
authors.affiliation: China Pharmaceutical University, Nanjing 21009, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ding
authors.affiliation: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China; The Forth Clinical School of Nanjing Medical University, Nanjing 210009, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.affiliation: Research Center of Clinical Oncology, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Chen
authors.affiliation: Research Center of Clinical Oncology, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Ma
authors.affiliation: Research Center of Clinical Oncology, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China.
authors.forename: Jian-Zhong
authors.initials: JZ
authors.lastname: Wu
authors.affiliation: Xuzhou Medical University, Xuzhou, Xuzhou 221004, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, China; Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: jinhangtangjsch@163.com.
authors.forename: Jin-Hai
authors.initials: JH
authors.lastname: Tang
mesh_terms: D033942:Adaptor Proteins, Vesicular Transport / Q000037:antagonists & inhibitors* / Q000235:genetics*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D061986:MCF-7 Cells; D035683:MicroRNAs / Q000235:genetics*; D009361:Neoplasm Invasiveness / Q000235:genetics; D043823:Taxoids / Q000494:pharmacology*; D014410:Tumor Stem Cell Assay; D015854:Up-Regulation
chemical_list: D033942:Adaptor Proteins, Vesicular Transport; D000970:Antineoplastic Agents; C560923:MIRN346 microRNA, human; D035683:MicroRNAs; C532615:SRCIN1 protein, human; D043823:Taxoids; D000077143:Docetaxel
keywords: Breast cancer; Chemosensitivity; Docetaxel; SRCIN1; miR-346